Emodin and Isoproterenol in Cardiac Hypertrophy: An Overview of Their Mechanisms, Potential Treatments, and Future Prospects

Jasmin Rashid Bagwan, Mujeeb Muhamadhusen Shaikh
Loknete shri Dadapatil Pharate College of Pharmacy

OVERVIEW

An adaptive response to elevated hemodynamic load or neurohormonal stimulation is cardiac hypertrophy. Prolonged hypertrophy, though initially compensatory, can result in maladaptive remodeling and cardiac failure. Characterizing the molecular mechanisms mediating hypertrophic responses is necessary to develop specific therapeutic strategies. Isoproterenol-induced cardiac hypertrophy is an established experimental paradigm mimicking sympathetic over activation seen in several cardiac diseases. Emodine, on the other hand, has been a focus of attention as a compound that possess cardioprotective, antioxidant and anti-inflammatory activities [2–4].. The purpose of this review is to summarize what is currently known about how emodine and isoproterenol interact with cardiac hypertrophy.

Cardiac Hypertrophy Overview

Individual cardiomyocytes swell during cardiac hypertrophy, increasing the bulk of the heart. Depending on the pattern of myocardial enlargement, it can be divided into concentric and eccentric hypertrophy categories. At the molecular level, signaling networks consist of β-adrenergic signaling cascade, calcineurin-NFAT pathway and PI3K-Akt pathway wherein those will regulate hypertrophy [6]. The persistent activation of these pathways can lead to fibrosis, pathological remodeling and impaired cardiac function. Cardiac hypertrophy is characterized by the swelling of individual cardiomyocytes, to increase heart mass. As a result, myocardial hypertrophy can be classified into 2 classifications (concentric or eccentric) according to the pattern of enlargement that appears. At the molecular level, sympathetically activated signaling networks such as β-adrenergic signaling pathway, calcineurin-NFAT and PI3K-Akt pathways control hypertrophy. Continuous activation of these pathways can result in fibrosis, pathological remodeling, and impaired cardiac function.

Mechanisms of Action of Isoproterenol

1. β-Adrenergic Receptor Activation: ISO raises cAMP levels and activates adenylate cyclase via binding to β-adrenergic receptors.
2. Activation of Protein Kinase A (PKA): PKA activation increased cAMP, which phosphorylates many substrates, including ion channels and transcription factors.
3. Calcium Handling: The PKA-dependent phosphorylation disrupts calcium balance regulating calcium influx and efflux.
4. Oxidative Stress: ISO is a potent stimulus of the β-adrenergic system, resulting in increased levels of reactive oxygen species (ROS), ultimately leading to oxidative injury.
5. Gene expression: Activation of hypertrophic gene programs, (eg, brain natriuretic peptide [BNP] and atrial natriuretic peptide [ANP])

Emodine's composition, history, and pharmacological properties

Emodine, a plant derivative of an anthraquinone, is extracted from plants such as Rheum palmatum and Polygonum cuspidatum. Its chemical structure is a three-ring anthraquinone backbone with hydroxyl and methoxy substituents, which contributes to its pharmacological effects.

Emodine's Pharmacological Effects

1. Antioxidant Activity: Emodine lowers oxidative stress by scavenging free radicals.
2. Anti-Inflammatory Effects: It alters inflammatory signaling pathways and suppresses pro-inflammatory cytokines.
3. Cardioprotective Properties: Emodine protects against hypertrophic reactions, arrhythmias, and ischemia-reperfusion damage.

4. Apoptosis Regulation: It enhances cell survival in stressful situations by modifying apoptotic pathways.

The Role of Emodine in Cardiac Hypertrophy

According to new research, emodine may reduce heart hypertrophy in a number of ways:
1. Inhibition of β-Adrenergic Signaling: Emodine may reduce the hypertrophic stimulation from ISO by modulating the activation of β-adrenergic receptors.
2. Antioxidant Defense: By lowering oxidative stress, emodine protects cardiomyocytes from harm brought on by ROS.
3. Anti-Fibrotic Effects: By inhibiting collagen deposition and fibroblast proliferation, emodine stops undesirable remodeling.
4. Modulation of Hypertrophic Signaling Pathways: It affects key signaling molecules such as NF-κB, MAPKs, and the PI3K-Akt pathway, which lowers the production of hypertrophic genes.

Evidence from Tests

Numerous in vitro and in vivo studies have demonstrated that emodine effectively reduces ISO-induced hypertrophy markers.

- Decrease in Heart Weight-to-Body Weight Ratio: Compared to animals treated with ISO alone, those treated with emodine had lower ratios.
- Decreased Expression of ANP and BNP: Emodine prevents the overexpression of hypertrophic biomarkers brought on by ISO.
- Better Cardiac Function: Echocardiographic assessments show that those taking emodine had better cardiac function.
- Histological Improvements: Emodine decreases myocyte hypertrophy and interstitial fibrosis in ISO-produced models.

The molecular processes that underlie the protective effects of emodine

Pathways of Antioxidants
Emodine prevents ISO-induced ROS buildup by increasing the production of endogenous antioxidant enzymes including catalase and superoxide dismutase (SOD).
Reduced Inflammatory Processes
Emodine lowers the production of pro-inflammatory cytokines including TNF-α and IL-6, which are linked to hypertrophic remodeling, by blocking NF-κB activation.
Changing the Signaling Pathways
The MAPK and PI3K-Akt pathways, which are essential for cardiomyocyte development and survival, are disrupted by emodine. Additionally, it affects the calcineurin-NFAT pathway, which reduces the transcriptional activation of genes that are hypertrophic.
The inhibition of apoptosis
Emodine promotes cardiomyocyte survival during hypertrophic stress by downregulating pro-apoptotic factors (like Bax) and upregulating anti-apoptotic proteins (like Bcl-2).

Possible Applications and Therapeutic Consequences

Because of its cardioprotective properties, emodine may be a useful medication for halting or reversing cardiac hypertrophy. Important pathogenic processes in hypertrophic remodeling are targeted by its several techniques, which include anti-inflammatory, anti-fibrotic, and antioxidant effects. Furthermore, emodine's ability to modify significant signaling pathways creates opportunities for combination therapies that target many aspects of cardiac hypertrophy.

Obstacles and Prospects

Despite the promising preclinical data, a series of questions remain to be addressed:
Delivering emodine for therapeutic use requires knowledge of its pharmacokinetic profile as well as measures to enhance its bioavailability.
Safety and Toxicity: Very little is known about the long-term safety of emodine, or if there are any adverse effects.
Clinical Trials: Translational research and clinical trials are required to verify the efficacy in humans of emodine.
Mechanistic momentum: Contrary to this therapeutic potential of emodine, clarity regarding the events in genome (biological), epigenome (non-biological), and transcriptome is much needed by elucidating molecular targets and interactions.

CONCLUSION

Emodine appears to be a novel and attractive agent for attenuation of isoproterenol-induced heart hypertrophy because of its anti-inflammatory as well as antioxidant and modulatory action on hypertrophic signaling pathways. While the foundation for its

cardioprotective role is preclinical, clinical studies are needed to translate these findings into clinical applications. Emodine may be a new and gender roles based treatment tool against cardiac hypertrophy and heart failure.

REFERENCES

[1] Xue, H., Meng, L., & Gao, X. (2019). Emodin alleviates isoproterenol-induced cardiac hypertrophy by regulating oxidative stress and inflammatory pathways. Cardiovascular Research, 115(6), 1255–1267.

[2] Wang, Z., Wu, Q., & Zhang, L. (2020). Anti-inflammatory and antioxidant properties of emodin: Potential applications in cardiac hypertrophy management. Journal of Molecular Medicine, 98(8), 1043–1054.

[3] Patel, D., & Dhingra, S. (2018). The role of β-adrenergic signaling in cardiac hypertrophy: Insights from isoproterenol-induced models. Frontiers in Physiology, 9, 1767

[4] Lee, J. Y., Park, S. J., & Kim, K. H. (2021). Emodin's cardioprotective role in experimental models of heart failure: Mechanistic insights and therapeutic potential. Pharmacological Reports, 73(4), 997–1006.

[5] Zhang, H., Chen, J., & Xiong, Q. (2019). Targeting MAPK and PI3K-Akt signaling pathways in cardiac hypertrophy: The role of emodin. Biochemical Pharmacology, 165, 130–141.

[6] Li, X., Wang, Y., & Guo, C. (2017). Protective effects of emodin on isoproterenol-induced myocardial hypertrophy in rats. Life Sciences, 184, 75–81.

[7] Cheng, L., Li, P., & Zhang, Q. (2020). Emodin's role in regulating calcium handling and reducing arrhythmogenesis in cardiac cells under hypertrophic stress. Pharmacological Research, 159, 104991.

[8] Jones, P. D., Kwan, T., & Leung, W. Y. (2016). The impact of β-adrenergic receptor activation on cardiac hypertrophy: Mechanisms and pharmacological interventions. Journal of Cardiovascular Pharmacology, 68(3), 233–240.

[9] Huang, Y., Zhao, Y., & Yu, C. (2018). Anti-fibrotic effects of emodin in cardiac remodeling: Insights into molecular mechanisms. International Journal of Molecular Sciences, 19(2), 393.

[10] Kumar, A., Gupta, V., & Sharma, S. (2021). Cardioprotective and anti-inflammatory effects of plant-derived anthraquinones: A review on emodin. Journal of Ethnopharmacology, 278, 114213.

[11] Nakamura, M., & Sadoshima, J. (2018). Mechanisms of hypertrophic growth in the heart: Insights from isoproterenol-induced models. American Journal of Physiology-Heart and Circulatory Physiology, 314(4), H793–H802.

[12] Wei, W., Wu, M., & Wang, P. (2019). Modulation of pro-inflammatory cytokines and oxidative stress by emodin in hypertrophic myocardium. Cellular Physiology and Biochemistry, 52(6), 1312–1323.

[13] Zhang, T., Zhao, X., & Liu, C. (2020). The therapeutic potential of emodin in cardiovascular diseases: Focus on cardiac hypertrophy and heart failure. Therapeutic Advances in Cardiovascular Disease, 14, 1–12.

[14] Bers, D. M. (2001). Excitation-Contraction Coupling and Cardiac Contractile Force (2nd ed.). Dordrecht:

[15] Opie, L. H., & Gersh, B. J. (2013). Drugs for the Heart (8th ed.). Philadelphia: Elsevier Saunders.

[16] Braunwald, E., Zipes, D. P., & Libby, P. (2018). Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine (11th ed.). Philadelphia: Elsevier.

[17] Rang, H. P., Dale, M. M., & Ritter, J. M. (2020). Rang & Dale's Pharmacology (9th ed.). London: Elsevier.

[18] Shah, A. M., Wong, M., & Tang, C. (2018). Heart Failure: Pathophysiology and Management. London: Springer.

[19] Waller, D. G., & Sampson, A. P. (2017). Medical Pharmacology and Therapeutics (5th ed.). London: Elsevier.

[20] Cragg, G. M., & Newman, D. J. (2005). Natural Products as Sources of Drugs. Basel: Springer.

[21] Foëx, P., & Sear, J. W. (2009). β-Adrenergic Blockade in Cardiovascular Medicine. Oxford: Oxford University Press.